Clinical Trials Browser

Interventional × monalizumab × 1 year × Clear all

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT05903092 2026-03-12

MOZART

Phase 2 Suspended

84 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT05061550 2026-03-11

NeoCOAST-2

Phase 2 Recruiting

630 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06503614 2026-02-17

ENHANCE

Phase 2 Recruiting

60 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05221840 2026-01-27

PACIFIC-9

Phase 3 Active not recruiting

1,051 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06769126 2026-01-22

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Phase 2 Recruiting

900 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03801902 2025-09-23

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Phase 1 Completed

26 enrolled 17 charts

Thoracic

Lung Neoplasms

NCT06892223 2025-03-24

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

Phase 2 Recruiting

42 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Clinical Trials

INTERLINK-1

MOZART

NeoCOAST-2

ENHANCE

PACIFIC-9

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation